Evinova

Bon dia from Barcelona! We’re excited to be attending the #REPharma event this week, learning from peers and participating in industry-shaping conversations around practical AI adoption for pharma, digital acceleration, patient engagement and so much more. If you are here too and want to connect, drop us a line! Reuters Events Pharma, Gabriela Feldberg, Shawn Tedman, Will Wilson

Congrats to Evinova’s Evan Grunbaum, a contributing author on Society of Quality Assurance's new ebook on data integrity! As adoption of AI in health care and clinical research continues to rise, understanding data integrity practices and principles is increasingly critical. We’re grateful to have quality experts like Evan who “wrote the book” on our team shaping our strategy. Check out more info below! #clinicaltrialtechnology #dataintegrity 

China is a key player in the global clinical trial landscape, with a booming life science sector and the number of registered trials steadily increasing year-over-year to outpace other major markets. We’re thrilled to join clinical trial experts and leaders in China for the dTrial Forum 2025, speaking about how Evinova is optimizing trials through digital innovation and AI.   Will you be there? Send us a message and let’s connect!   #ClinicalTrials #ArtificialIntelligence #ClinicalInnovation Gillian Livock MBA, Nate Zhang, Jieru H.

Don’t miss the webinar "Unlocking Impact Through Investment: Building the Business Case for Digital Endpoints" *today* March 26th featuring Libby Floden, Biostatistician and Head of Endpoints at Evinova. This event will unveil new resources to support the adoption of digital endpoints in clinical trials, including an ROI calculator, business case templates, and real-world case studies. Learn how to demonstrate the value of digital endpoints to decision-makers and build a compelling business case for investment in clinical trials. Register for the webinar here - https://lnkd.in/dEYtTQ47

Ready for #AACR25?   Evinova’s Dr. Ramya Palacholla will present a poster about our digital solution in development to monitor skin toxicities (e.g., maculo-papular rash, xerosis, or pruritis) during cancer trials. The data will showcase Evinova’s remote patient monitoring (RPM) module featuring several innovative components for reliable and sustained data capture of the onset and evolution of skin symptoms, including skin image capture and a 3D body avatar. This solution aims to provide real-time insights to HCPs monitoring patients at-risk of developing skin toxicities that can hinder the optimal dosing of cancer medicines.   Will you be #AACR25 and want to connect? Send us a message and our team will get back to you. In the meantime, learn more about Evinova’s RPM approach: https://lnkd.in/eTPQy-Sq   #newdata #cancerresearch #oncologytrials #clinicaltrialtechnology 

We're pleased to share that Quantum Leap Healthcare Collaborative will incorporate Evinova’s remote patient monitoring (RPM) solution into the I-SPY 2.2 breast cancer trial.   Interstitial lung disease (ILD) is a potential serious side effect for some cancer therapies such as antibody drug conjugates. Evinova’s pulmonary RPM module enables real-time monitoring of patients between clinical visits and alerts healthcare providers of the potential onset or worsening of ILD symptoms. With this information, sites can intervene promptly based on guidelines, potentially reducing the likelihood of progression to high-grade ILD and dose reduction, hold or interruption of treatment.   Learn more about our collaboration here: https://lnkd.in/eTfvEJXn   #remotepatientmonitoring #breastcancerresearch #clinicaltrialtechnology #patientcentricity 

It was great to connect at #WorldADCLondon. As a science-led company, we’re passionate about delivering digital solutions that improve the patient experience with clinical trials and support optimal health outcomes from the next generation of transformative medicines.   Are you considering remote patient monitoring for your ADC research? Please reach out – our team of experienced strategists and scientists can help. https://lnkd.in/egEKBznc #forhealthcarebyhealthcare

Antibody-drug conjugates (ADCs) hold tremendous promise in cancer research but carry nuanced toxicity risks that require a data‑driven approach to dosing.   At Evinova, we work with drug developers to address the specific challenges of ADC toxicity monitoring. Our remote patient monitoring (RPM) modules are fit-for-purpose solutions to alert healthcare providers of the onset of symptoms of common ADC adverse events such as interstitial lung disease, nausea, vomiting, diarrhea or dehydration. This data enables HCPs to intervene proactively and make decisions about dosing in adherence with treatment guidelines.   Discover how our technology supplements your ADC drug development strategy: https://lnkd.in/evTH29ke    #WorldADCLondon

The Evinova team is attending #WorldADCLondon next week!    We’re excited to learn from global experts about the latest updates in antibody-drug conjugate (ADC) development and discuss how our effective, easy-to-use digital solutions can support optimal ADC dosing and adherence to treatment management guidelines to drive better patient outcomes.    Will you be there and want to connect? Fill out this form and our team will follow up: https://lnkd.in/eYMBeEQf    World ADC Event Series: Gillian Livock MBA, James Thatcher, Will Wilson, Luis Garcia-Gancedo

Next week, don’t miss our Chief Commercial Officer, Gillian Livock MBA, at the BioIndustry Association (BIA) #WomeninBiotech event in Cambridge.    Gill will join a panel of experts to discuss how greater diversity in data and clinical trials can lead to better healthcare outcomes.   Register here - https://lnkd.in/e5ZBCfZQ